DanaMeredithChaseMDMD, FACOG(She/Her)
Obstetrics & Gynecology • Los Angeles, CAGynecologic Oncology
Associate Professor, Obstetrics and Gynecology
Dr. Chase is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz Ste 220
Los Angeles, CA 90095Phone+1 310-794-7274Fax+1 520-519-7910
Summary
- Dr. Dana Chase is a Gynecologic Oncologist with the David Geffen School of Medicine at UCLA. She received her medical degree, residency and fellowship from University of California Irvine School of Medicine and has been in practice as a Gynecologic Oncologist since 2011. She speaks Spanish fluently. She specializes in gynecologic cancers and has performed over 1500 robotic surgeries. She is a clinical trial investigator and has special interest in chemotherapy for ovarian, cervical and/or uterine cancers.
Education & Training
University of California (Irvine)Fellowship, Gynecologic Oncology, 2007 - 2011- University of California (Irvine)Residency, Obstetrics and Gynecology, 2003 - 2007
University of California, Irvine, School of MedicineClass of 2003
Certifications & Licensure
AZ State Medical License 2011 - 2026
CA State Medical License 2005 - 2025- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- 28 citationsSurgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approachElizabeth Burton, Dana M. Chase, Maki Yamamoto, Jayson de Guzman, David K. Imagawa
Gynecologic Oncology. 2011-01-01 - 55 citationsPredictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.Ernest Han, Robert A. Burger, Kathleen M. Darcy, Michael W. Sill, Leslie M. Randall
Gynecologic Oncology. 2010-12-01 - 2 citationsThe impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.Dana M Chase, Anadi Mahajan, David Alexander Scott, Neil Hawkins, Linda Kalilani
BMC Women's Health. 2024-03-15
Press Mentions
The Drug Zejula Shows Important Long-Term, Progression-Free Survival Benefit for Patients with Advanced Ovarian CancerOctober 13th, 2022- Bringing Discoveries to the Patient’s BedsideMarch 3rd, 2022
Analyses Underscore Extent of Frontline Maintenance Niraparib Benefit in Ovarian CancerApril 10th, 2020- Join now to see all
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
